Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine/Ketotifen Combination for Allergic Conjunctivitis
NCT05579730Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brimonidine + ketotifen in allergic conjunctivitis (AC), sponsored by Bausch + Lomb. Started Oct 2022; status: completed.
02
Drugs
brimonidine + ketotifen
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT05579730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579730.